Bioinformatic evidences and analysis of putative biomarkers in pancreatic ductal adenocarcinoma. Issue 8 (August 2019)

• Record Type: Journal Article
• Authors: Gu, Yuan; Feng, Qijin; Liu, Han; Zhou, Qi; Hu, Ailing; Yamaguchi, Takuji; Xia, Shilin; Kobayashi, Hiroyuki
• Is Part Of: Heliyon. Volume 5:Issue 8(2019)
• Publication Date: 2019-08
• Subjects: Bioinformatics -- Cancer research -- Oncology -- Diagnostics -- Biomarkers -- Differentially expressed genes -- Protein-protein interaction -- Bioinformatic analysis -- Pancreatic ductal adenocarcinoma; Research -- Periodicals; Medical sciences -- Periodicals; Natural history -- Periodicals; Social sciences -- Periodicals; Earth sciences -- Periodicals; Physical sciences -- Periodicals; 507.2
• DOI: 10.1016/j.heliyon.2019.e02378
• Languages: English
• ISSNs: 2405-8440

Abstract

Abstract: Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers. Aberrant expression of genes plays important role in the procession of PDAC. The analysis of gene expression profile will contribute to the research of carcinoma mechanism. Objective: This present study is focused to investigate the differentially expressed genes (DEGs) from 3 PDAC microarray datasets, which would provide candidate genes for putative biomarkers to understand the mechanism of PDAC and potential targets of treatment. Method: Based on the overlap genes obtained from 3 GEO datasets, the hub genes were identified using STRING and Cytoscape plugin MCODE. The enrichment and function analysis were applied using DAVID. The protein-protein interaction network was performed using cBioPortal and UCSC Xena. The Oncomine was finally used to determine the candidate gene by analyzing their expression between pancreas sample and PDAC sample. Results: 25 hub genes were selected from a total of 1006 DEGs from 3 GEO datasets, consisting of 14 upregulated genes and 11 downregulated genes. The overall decline of hub gene expression enriched in G1 phase of cell cycle in other subtypes of pancreatic cancer. Oncomine database was ultimately performed to determine the 8 candidate genes, including CXCL5, CCL20, NMU, F2R, ANXA1, EDNRA, LPAR6, and GNA15. Conclusions: Conclusively, 8 candidate genes would become the potential PDAC combined biomarkers for diagnosis and therapeutic strategies.